Netherlands· NL-7f01160eafde

Giotrif 30 mg, filmomhulde tabletten

A afatinib product containing afatinibdimaleaat, registered in Netherlands by Boehringer Ingelheim International GmbH. The same ATC class is registered in 12 of our 19 countries.

ATC L01EB03

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about afatinibdimaleaatAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Afatinib is registered in 12 of 19 countries.

Countries holding a registration under ATC L01EB03 (afatinib), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
8 of them publish a price we can compare per daily dose

Search afatinib products by name

Afatinib · ATC L01EB03

12 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Icelandprice
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of afatinib costs, country by country.

Normalised to the WHO defined daily dose (40 mg), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Afatinib · price per daily dose (40 mg)

USD · FX 28 Sept 2026

CH Switzerland$199.66

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: AFATINIBDIMALEAAT
Manufacturer: Boehringer Ingelheim International GmbH
Country: Netherlands (NL)
ATC code: L01EB03
ATC class: Afatinib
Defined daily dose: 40 mg, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/13/879

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

170 interactions on record for afatinib.

Graded by severity as the source publishes them — 10 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check afatinib against other medicines How interaction checks work

Afatinib · interactions on record

170 records

10 severe
158 moderate
2 minor

Most severe, free to view

MipomersenC10AX11severe
LomitapideC10AX12severe
PexidartinibL01EX15severe
Aminolevulinic acidL01XD04severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Afatinib in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All afatinib products

Authorised across Europe · EMA

The same active substance is authorised in 8 EEA countries. Names it is sold under:

Cyprus · Afatinib Afatinib, Afatinib Sapiens
Greece · Webrix
Iceland · Giotrif
Liechtenstein · Giotrif
Latvia · Afatinib, Afatinib Lotus
Malta · Afatinib Lotus
Norway · Giotrif
Sweden · Afatinib Lotus, Webrix

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/3d73b7a1-41e8-4002-bc74-507868435133
GET /v1/drugs/3d73b7a1-41e8-4002-bc74-507868435133?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Afatinib",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp112737",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSPOVIDON (E 1202)",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "INDIGOKARMIJN ALUMINIUMLAK (E 132)",
    "LACTOSE 1-WATER",
    "MACROGOL 400",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POLYSORBAAT 80 (E 433)",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "AFATINIBDIMALEAAT"
  ],
  "leaflet_url": null,
  "authorised_at": "2013/09/25",
  "procedure_number": "EMEA/H/C/002280",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/13/879",
  "additional_monitoring": "Y"
}

API reference MCP server Plans

See everything about afatinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console